黄芪甲苷对人外周血单个核细胞内HBV表达的影响

Effect of Astragaloside IV on HBV Expression in Human Peripheral Blood Mononuclear Cell

目的:探索黄芪甲苷对乙肝后肝硬化患者外周血单个核细胞(PBMC)内HBV表达的影响。方法:选取2019年2月—2022年2月于江西省人民医院就诊的20例乙肝后肝硬化患者,分离并培养外周血单个核细胞,依据培养液所含药物类型分为对照组、拉米夫定组、黄芪甲苷组。拉米夫定组和黄芪甲苷组又根据药物终浓度各分为低、中、高浓度3个亚组。培养1周后,分别检测各组HBsAg、HBeAg、HBV-DNA、HBV-cccDNA表达。结果:与对照组相比,黄芪甲苷各浓度组HBsAg表达量均显著降低,差异具有统计学意义(P<0.05);黄芪甲苷各浓度组HBeAg表达量无统计学差异(P>0.05),黄芪甲苷低浓度组HBV-DNA表达量无统计学差异(P>0.05),黄芪甲苷中、高浓度组HBV-DNA表达量显著降低,差异具有统计学意义(P<0.05),黄芪甲苷各浓度组HBV-cccDNA表达量无统计学差异(P>0.05)。与对照组相比,拉米夫定各浓度组HBsAg、HBeAg、HBV-DNA表达量均显著降低,差异具有统计学意义(P<0.05);拉米夫定低浓度组HBV-cccDNA表达量无统计学差异(P>0.05),拉米夫定中、高浓度组HBV-cccDNA表达量显著降低,差异具有统计学意义(P<0.05)。Spearman检验分析提示黄芪甲苷浓度与HBsAg、HBeAg、HBV-DNA、HBV-cccDNA表达量呈线性负相关,其中与HBsAg、HBV-DNA的负相关性有统计学意义(P<0.05)。结论:黄芪甲苷能够在一定程度上抑制乙肝后肝硬化患者PBMC中HBV的复制,能为解决肝移植术后HBV复发提供新的治疗思路。

Objective:To explore the effect of astragaloside IV on the expression of HBV in peripheral blood mononuclear cell(PBMC)of patients with post-hepatitis B cirrhosis.Methods:Twenty patients with post-hepatitis B cirrhosis who were treated in jiangxi provincial people's hospital from February 2019 to February 2022 were selected.PBMCs were isolated and cultured,and then divided into control group,lamivudine group and astragaloside IV group according to the type of drugs contained in the culture medium.The lamivudine group and astragaloside IV group were further divided into three subgroups with low,medium and high concentration according to the final concentration of the drug.After culturing for 1 week,the expressions of HBsAg,HBeAg,HBV-DNA and HBV-cccDNA were detected in each group.Results:Compared with the control group,the expression of HBsAg in each concentration group of astragaloside IV was significantly decreased,and the difference was statistically significant(P<0.05),while the expression of HBeAg in each concentration group of astragaloside IV had no statistical difference(P>0.05).There was no significant difference in the expression of HBV-DNA in the low concentration group of astragaloside IV(P>0.05).The expression of HBV-DNA in the middle and high concentration groups of astragaloside IV decreased significantly,and the difference was statistically significant(P<0.05).There was no significant difference in the expression of HBV-cccDNA in each concentration group of astragaloside IV(P>0.05).Compared with the control group,the expressions of HBsAg,HBeAg,and HBV-DNA in each concentration group of lamivudine were significantly decreased,and the difference was statistically significant(P<0.05).There was no significant difference in the expression of HBV-cccDNA in the lamivudine low concentration group(P>0.05).The expression of HBV-cccDNA in the middle and high concentration groups of lamivudine was significantly decreased,and the difference was statistically significant(P<0.05).Spearman test analysis indicated that the concentration of astragaloside IV was linearly and negatively correlated with the expression levels of HBsAg,HBeAg,HBV-DNA,and HBV-cccDNA,and the negative correlation with HBsAg and HBV-DNA was statistically significant(P<0.05).Conclusion:Astragaloside IV can inhibit HBV replication in PBMC of patients with post-hepatitis B cirrhosis to a certain extent,which can provide a new therapeutic idea to address HBV relapse after liver transplant.